title: Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy.
abstract: The IgA and IgG antibody response to plasmid-encoded outer membrane proteins was studied in 59 patients with yersinia-associated spondylarthropathy during 15 months of follow-up. Initially, all patients had specific IgA and IgG antibodies to the 36 and 46 kDa and 30% also to the 26 and 58 kDa released proteins, which correlated with the finding of virulent Yersinia bacilli in intestinal biopsies. IgA disappeared in 69% of untreated patients after nine months and persisted in 31% after one year. IgA disappeared within three to six months in 81% of the patients treated with antibiotics for four to six weeks and persisted in 6% after one year (p less than 0.002). IgG antibodies to the 36 and 46 kDa outer membrane proteins persisted in 80% of all patients. Disappearance of IgA was coupled with disappearance of yersinia from intestinal biopsies.
authors.affiliation: Laboratory for Public Health, Leeuwarden, The Netherlands.
authors.forename: J A
authors.initials: JA
authors.lastname: Hoogkamp-Korstanje
authors.forename: J
authors.initials: J
authors.lastname: de Koning
authors.forename: J
authors.initials: J
authors.lastname: Heesemann
authors.forename: J J
authors.initials: JJ
authors.lastname: Festen
authors.forename: P M
authors.initials: PM
authors.lastname: Houtman
authors.forename: P L
authors.initials: PL
authors.lastname: van Oyen
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy / Q000276:immunology*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D007422:Intestines / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D013166:Spondylitis / Q000188:drug therapy / Q000276:immunology; D013997:Time Factors; D014295:Trimethoprim / Q000627:therapeutic use; D015009:Yersinia Infections / Q000188:drug therapy / Q000276:immunology*; D015008:Yersinia enterocolitica / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D002939:Ciprofloxacin; D014295:Trimethoprim; D004318:Doxycycline